One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024-07 · 44 (7)
DOI: 10.1161/atvbaha.124.321058 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024-07. Verfasst von Rosangela Akemi Hoshi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine (R.A.H., P.M.R., H.L.-G., S.M.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Rosuvastatin Calcium, Cardiovascular Diseases, Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Statin effects extend beyond low-density lipoprotein cholesterol reduction, potentially modulating the metabolism of bioactive lipids (BALs), crucial for biological signaling and inflammation. These bioactive metabolites may serve as metabolic footprints, helping uncover underlying processes linked to pleiotropic effects of statins and yielding a better understanding of their cardioprotective properties. This study aimed to investigate the impact of high-intensity statin therapy versus placebo on plasma BALs in the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; NCT00239681), a randomized primary prevention trial involving individuals with low-density lipoprotein cholesterol
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine (R.A.H., P.M.R., H.L.-G., S.M.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Division of Preventive Medicine (R.A.H., Y.L., P.M.R., R.J.G., H.L.-G., M.V.M., O.V.D., S.M.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Center for Lipid Metabolomics (R.A.H., Y.L., H.L.-G., O.V.D., S.M.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Department of Medicine (M.A., J.D.W., M.J.), University of California San Diego, La Jolla.
- Division of Pulmonary, Critical Care and Sleep Medicine (M.A.), University of California San Diego, La Jolla.
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine (C.N.S.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
ORCID-Profile: Rosangela Akemi Hoshi, Mona Alotaibi, Paul M Ridker, Robert J Glynn, Charles N Serhan, Heike Luttmann-Gibson, Olga V Demler, Samia Mora
Förderung
- American Heart Association-American Stroke Association
- NHLBI NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Hoshi, R. A., Alotaibi, M., Liu, Y., Watrous, J. D., Ridker, P. M., Glynn, R. J., Serhan, C. N., Luttmann-Gibson, H., Moorthy, M. V., Jain, M., Demler, O. V., & Mora, S. (2024). One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 44(7). https://doi.org/10.1161/atvbaha.124.321058
Vancouver
Hoshi RA, Alotaibi M, Liu Y, Watrous JD, Ridker PM, Glynn RJ, et al. One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44(7). doi:10.1161/atvbaha.124.321058
BibTeX
@article{Hoshi2024,
author = {Hoshi, Rosangela Akemi and Alotaibi, Mona and Liu, Yanyan and Watrous, Jeramie D and Ridker, Paul M and Glynn, Robert J and Serhan, Charles N and Luttmann-Gibson, Heike and Moorthy, M Vinayaga and Jain, Mohit and Demler, Olga V and Mora, Samia},
title = {One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
volume = {44},
number = {7},
doi = {10.1161/atvbaha.124.321058}
}
EUVIMED